KUPPUSAMY KARTHIK 4
4 · QUEST DIAGNOSTICS INC · Filed Aug 1, 2025
Insider Transaction Report
Form 4
KUPPUSAMY KARTHIK
SVP, Clinical Solutions
Transactions
- Exercise/Conversion
Common Stock
2025-07-30$86.63/sh+3,045$263,788→ 13,705 total - Sale
Common Stock
2025-07-30$167.40/sh−5,224$874,498→ 10,660 total - Sale
Common Stock
2025-07-30$167.40/sh−3,045$509,733→ 10,660 total - Sale
Common Stock
2025-07-31$170.00/sh−2,210$375,700→ 8,450 total - Exercise/Conversion
Non-Qualifed Stock Option (right to buy)
2025-07-30$86.63/sh−3,045$263,788→ 0 totalExercise: $86.63Exp: 2029-02-18→ Common Stock (3,045 underlying) - Exercise/Conversion
Non-Qualifed Stock Option (right to buy)
2025-07-30$112.17/sh−5,224$585,976→ 0 totalExercise: $112.17Exp: 2030-02-18→ Common Stock (5,224 underlying) - Exercise/Conversion
Common Stock
2025-07-30$112.17/sh+5,224$585,976→ 15,884 total
Holdings
- 1,629(indirect: By 401(k))
Common Stock
- 358(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
- [F2]These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
- [F3]The options vested in three annual installments beginning with the first on February 18, 2020, the second on February 18, 2021 and the final on February 18, 2022.
- [F4]The options vested in three annual installments beginning with the first on February 18, 2021, the second on February 18, 2022 and the final on February 18, 2023.